Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis

Fu,Dandan; Song,Xiangfeng; Hu,Hua; Sun,Min; Li,Zhanguo; Tian,Zhongwei

doi:10.3892/mmr.2016.5108

Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis

Authors:
- Dandan Fu
- Xiangfeng Song
- Hua Hu
- Min Sun
- Zhanguo Li
- Zhongwei Tian
View Affiliations

Affiliations: Department of Dermatology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China
Published online on: April 12, 2016 https://doi.org/10.3892/mmr.2016.5108
Pages: 4606-4612
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a common chronic inflammatory and T cell-meditated skin disease. Runt-related transcription factor 3 (RUNX3), one of the runt‑domain family of transcription factors, has been reported to be a susceptibility gene for psoriasis. The present study was designed to delineate the role and underlying mechanism of RUNX3 involved in the differentiation of T helper (Th) 17 and Th22 cells in psoriasis. The results of the present study demonstrated that the expression of RUNX3 increased significantly in CD4‑positive (CD4+) T cells from patients with psoriasis, compared with healthy controls. In addition, increased levels of interleukin (IL)‑6, IL‑20 and IL‑22, and increased frequencies of Th17 and Th22 cells were found in the patients with psoriasis patients, compared with the healthy controls. It was also found that the overexpression of RUNX3 increased the levels of Th17‑ and Th22‑associated cytokines in the CD4+ T cells from the healthy controls. However, the inhibition of RUNX3 reduced the levels of the associated cytokines and decreased the frequency of Th17 and Th22 cells in the CD4+ T cells from the patients with psoriasis. Taken together, the present study suggested that RUNX3 regulated the differentiation of Th17 and Th22 cells in psoriasis, providing a promising therapeutic strategy for the treatment of psoriasis.

View Figures

View References

1	Sales R and Torres T: Psoriasis and metabolic syndrome. Acta Dermatovenerol Croat. 22:169–174. 2014.PubMed/NCBI
2	Diani M, Altomare G and Reali E: T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 14:286–292. 2015. View Article : Google Scholar
3	Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H and Skapenko A: Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62:2876–2885. 2010. View Article : Google Scholar : PubMed/NCBI
4	Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, Bernard FX, Nau F, Guillet G, Dagregorio G, Yssel H, et al: A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol. 150:407–415. 2007. View Article : Google Scholar : PubMed/NCBI
5	Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, Bergman R, Krueger JG and Guttman-Yassky E: IL-22-producing ῾T22᾽ T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 123:1244–1252.e2. 2009. View Article : Google Scholar
6	Cauli A and Mathieu A: Psoriatic arthritis: Genetics and pathogenesis. Reumatismo. 64:71–78. 2012. View Article : Google Scholar : PubMed/NCBI
7	Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R and Gaston H: Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 15:R1362013. View Article : Google Scholar : PubMed/NCBI
8	Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, Cheng H, Qiu Y, Chen G, Mei J, et al: A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 46:45–50. 2014. View Article : Google Scholar
9	Garber K: Genetics: Deep exploration. Nature. 492(Suppl): S56–S57. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, et al: Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 44:1341–1348. 2012. View Article : Google Scholar : PubMed/NCBI
11	Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, Pasutto F, Ekici AB, McManus R, Ho P, et al: Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum. 65:1224–1231. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chen HX, Wang S, Wang Z, Zhang ZP and Shi SS: Overexpression of RUNX3 inhibits malignant behaviour of Eca109 cells in vitro and vivo. Asian Pac J Cancer Prev. 15:1531–1537. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yagi R, Junttila IS, Wei G, Urban JF Jr, Zhao K, Paul WE and Zhu J: The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity. 32:507–517. 2010. View Article : Google Scholar : PubMed/NCBI
14	Blyth K, Cameron ER and Neil JC: The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer. 5:376–387. 2005. View Article : Google Scholar : PubMed/NCBI
15	He SY, Jiang RF, Jiang J, Xiang YS and Wang L: Investigation of methylation and protein expression of the gene in colon carcinogenesis. Biomed Rep. 3:687–690. 2015.PubMed/NCBI
16	Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
17	Brenner O, Levanon D, Negreanu V, Golubkov O, Fainaru O, Woolf E and Groner Y: Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc Natl Acad Sci USA. 101:16016–16021. 2004. View Article : Google Scholar : PubMed/NCBI
18	Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, Negreanu V, Bernstein Y, Levanon D, Jung S and Groner Y: Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J. 23:969–979. 2004. View Article : Google Scholar : PubMed/NCBI
19	Naoe Y, Setoguchi R, Akiyama K, Muroi S, Kuroda M, Hatam F, Littman DR and Taniuchi I: Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. J Exp Med. 204:1749–1755. 2007. View Article : Google Scholar : PubMed/NCBI
20	Djuretic IM, Cruz-Guilloty F and Rao A: Regulation of gene expression in peripheral T cells by Runx transcription factors. Adv Immunol. 104:1–23. 2009. View Article : Google Scholar : PubMed/NCBI
21	Oji V and Luger TA: The skin in psoriasis: Assessment and challenges. Clin Exp Rheumatol. 93(Suppl 5): S14–19. 2015.
22	Wang G, Wang L, Sun S, Wu J and Wang Q: Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann Lab Med. 35:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ghoreschi K, Weigert C and Röcken M: Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 25:574–580. 2007. View Article : Google Scholar : PubMed/NCBI
24	Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB and Thomsen SF: Heritability of psoriasis in a large twin sample. Br J Dermatol. 169:412–416. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhou L, Chong MM and Littman DR: Plasticity of CD4+ T cell lineage differentiation. Immunity. 30:646–655. 2009. View Article : Google Scholar : PubMed/NCBI
26	Miossec P: IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 11:625–630. 2009. View Article : Google Scholar : PubMed/NCBI
27	van den Berg WB and McInnes IB: Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 43:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bettelli E, Korn T, Oukka M and Kuchroo VK: Induction and effector functions of T(H)17 cells. Nature. 453:1051–1057. 2008. View Article : Google Scholar : PubMed/NCBI
29	Peck A and Mellins ED: Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol. 132:295–304. 2009. View Article : Google Scholar : PubMed/NCBI
30	Volpe E, Battistini L and Borsellino G: Advances in T helper 17 cell biology: Pathogenic role and potential therapy in multiple sclerosis. Mediators Inflamm. 2015:4751582015. View Article : Google Scholar
31	Asarch A, Barak O, Loo DS and Gottlieb AB: Th17 cells: A new paradigm for cutaneous inflammation. J Dermatolog Treat. 19:259–266. 2008. View Article : Google Scholar : PubMed/NCBI
32	Duhen T, Geiger R, Jarrossay D, Lanzavecchia A and Sallusto F: Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 10:857–863. 2009. View Article : Google Scholar : PubMed/NCBI
33	Liu Y, Yang B, Zhou M, Li L, Zhou H, Zhang J, Chen H and Wu C: Memory IL-22-producing CD4+ T cells specific for Candida albicans are present in humans. Eur J Immunol. 39:1472–1479. 2009. View Article : Google Scholar : PubMed/NCBI
34	N, Pan HF and Ye DQ: Th22 in inflammatory and autoimmune disease: Prospects for therapeutic intervention. Mol Cell Biochem. 353:41–46. 2011. View Article : Google Scholar
35	Kaur S, Zilmer K, Leping V and Zilmer M: Comparative study of systemic inflammatory responses in psoriasis vulgaris and mild to moderate allergic contact dermatitis. Dermatology. 225:54–61. 2012. View Article : Google Scholar : PubMed/NCBI
36	Chandran V: Soluble biomarkers may differentiate psoriasis from psoriatic arthritis. J Rheumatol Suppl. 89:65–66. 2012. View Article : Google Scholar : PubMed/NCBI
37	Sabat R and Wolk K: Research in practice: IL-22 and IL-20: Significance for epithelial homeostasis and psoriasis pathogenesis. J Dtsch Dermatol Ges. 9:518–523. 2011.English, German. PubMed/NCBI
38	Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Vom Baur E, Witte K, Warszawska K, Philipp S, et al: IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl). 87:523–536. 2009. View Article : Google Scholar
39	Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Döcke WD, Asadullah K, Volk HD, et al: The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis. Eur J Immunol. 39:3570–3581. 2009. View Article : Google Scholar : PubMed/NCBI
40	Liang Y, Pan HF and Ye DQ: Therapeutic potential of STAT4 in autoimmunity. Expert Opin Ther Targets. 18:945–960. 2014. View Article : Google Scholar : PubMed/NCBI
41	Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI